美国 Singulex一种信息生物分析系统能够检测血液中的心脏肌钙蛋白I(cTnI)。cTnI是已知的心肌损害的生物医学标志物。
这种新型检测方法叫做Erenna，业已证实其诊断能力符合新近重新定义的急性心肌梗塞(AMI)诊断标准，已经得到了欧洲心脏学会和美国心脏学会的重视和推荐。
这种Erenna检测方法是由Singulex公司(Haywood, CA, USA)研制开发的，使用了获得专利的直接单分子检测技术以及用户自定义的临床检测方法，能够在亚皮克(pg)水平定量检测具有治疗意义的生物标志物。研究显示Erenna能够显著降低样本背景，能够鉴别检测来自其他分子的染料，检测结果具有良好的可重复性和较好的信/噪比。
The Erenna Immunoassay System
The Erenna Immunoassay System is the most sensitive immunoassay instrument available, utilizing patented digital single-molecule detection for high-precision quantification of low-abundance biomarkers.
The proprietary background reduction methodology extends the dynamic range to over 4 logs, allowing researchers and drug developers to use biomarkers to measure drug efficacy, safety, disease state and disease progression. Singulex immunoassays offer improved sensitivity, precision, and specificity over existing assay methods.
The Erenna Immunoassay System includes a fully integrated benchtop analytical instrumentation with dedicated software for automated data analysis.
Minimum Performance Specifications:
| Slope |
>20 DE/fM* |
| Background |
< 100 DE |
| LoD |
< 1 fM* |
| Precision |
< 7% CV** |
| Dyamic Range |
> 4 logs |
*Determined from calibrator set: 0-300 fM of 150kD antibody labeled with fluorophore.
** DE measurements from 30 fM calibrator, n=20.
The Erenna Immunoassay System is for research use only. Click on the following links for more information:
- download Erenna product brochure
- download instrumentation specifications
- view available immunoassays
|
 |
Erenna产品手册: http://www.singulex.com/documents/brochures/05-0376-00_Erenna_Product_Brochure.pdf
仪表规范:http://www.singulex.com/documents/brochures/05-0340-00_Erenna_Immunoassay_System_Flyer.pdf